Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenibPhilippe Saïag, Caroline Dutriaux, H. Maillard et al.|European Journal of Cancer|2021Cited by 13
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastasesCaroline Dutriaux, Philippe Saïag, Caroline Robert et al.|European Journal of Cancer|2022Cited by 13
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Alexander C. J. van Akkooi, Michal Kiciński et al.|The Lancet Oncology|2025Cited by 10
Resistances to vismodegibs in a French case series of 207 patients with locally advanced basal cell carcinoma.Nicole Basset‐Séguin, Fred de Sauvage, Hayley J. Sharpe et al.|Journal of Clinical Oncology|2016Cited by 2
An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanomaPhilippe Saïag, Caroline Dutriaux, Caroline Robert et al.|Annals of Oncology|2018Cited by 1